{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:12:54Z","timestamp":1785521574449,"version":"3.56.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>There are increasing concerns about the negative impacts of chemotherapy near the end of life (EOL). There is discrepancy among different countries about its use, and little is known about the real-world situation in China.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods<\/jats:title>\n                  <jats:p>This retrospective study was conducted at six representative hospitals across China. Adult decedents with a record of advanced solid cancer and palliative chemotherapy were consecutively screened from 2010 through 2014. The prevalence of EOL chemotherapy within the last 1 month of life was set as the primary outcome. The correlations among EOL chemotherapy, clinicopathological features, and overall survival (OS) were investigated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 3,350 decedents who had had cancer were consecutively included; 2,098 (62.6%) were male and the median age was 56 years (range, 20\u201388). There were 177 (5.3%), 387 (11.6%), and 837 (25.0%) patients who received EOL chemotherapy within the last 2 weeks, 1 month, and 2 months of life, respectively. We identified inferior OS (median OS, 7.1 vs. 14.2 months; hazard ratio, 1.37; 95% confidence interval [CI], 1.23\u20131.53; p &amp;lt; .001), more intensive treatments (e.g., admitted to intensive care unit [ICU] in the last month of life, received cardiopulmonary resuscitation and invasive ventilation support), and hospital death (odds ratio, 1.53; 95% CI, 1.14\u20132.06; p\u2009=\u2009.005) among patients who received continued chemotherapy within the last month compared with those who did not. However, subgroup analyses indicated that receiving oral agents correlated with fewer ICU admissions and lower rates of in-hospital death.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This study showed that EOL chemotherapy is commonly used in China. Intravenous chemotherapy at the EOL significantly correlated with poor outcomes and the role of oral anticancer agents warrants further investigation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2016-0013","type":"journal-article","created":{"date-parts":[[2016,10,28]],"date-time":"2016-10-28T02:43:30Z","timestamp":1477622610000},"page":"53-60","source":"Crossref","is-referenced-by-count":14,"title":["Chemotherapy Near the End of Life for Chinese Patients with Solid Malignancies"],"prefix":"10.1093","volume":"22","author":[{"given":"Jin","family":"Sheng","sequence":"first","affiliation":[{"name":"Medical Oncology of Sun Yat-sen University Cancer Center, Guangzhou, People\u2019s Republic of China"},{"name":"State Key Laboratory of Oncology in South China, Guangzhou, People\u2019s Republic of China"},{"name":"Collaborative Innovation Center for Cancer Medicine, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Xiong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Medical Oncology of Sun Yat-sen University Cancer Center, Guangzhou, People\u2019s Republic of China"},{"name":"State Key Laboratory of Oncology in South China, Guangzhou, People\u2019s Republic of China"},{"name":"Collaborative Innovation Center for Cancer Medicine, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Bo","family":"He","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Feng","family":"Fang","sequence":"additional","affiliation":[{"name":"Medical Oncology of Sun Yat-sen University Cancer Center, Guangzhou, People\u2019s Republic of China"},{"name":"State Key Laboratory of Oncology in South China, Guangzhou, People\u2019s Republic of China"},{"name":"Collaborative Innovation Center for Cancer Medicine, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Peng","family":"Yang","sequence":"additional","affiliation":[{"name":"Medical Oncology of Sun Yat-sen University Cancer Center, Guangzhou, People\u2019s Republic of China"},{"name":"State Key Laboratory of Oncology in South China, Guangzhou, People\u2019s Republic of China"},{"name":"Collaborative Innovation Center for Cancer Medicine, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui-Nan","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Zhongshan City People\u2019s Hospital, Zhongshan, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Peking University Shenzhen Hospital, Shenzhen, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, People\u2019s Republic of China"},{"name":"Henan Cancer Hospital, Zhengzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Zhu","family":"Zhai","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Yuan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Medical Oncology of Sun Yat-sen University Cancer Center, Guangzhou, People\u2019s Republic of China"},{"name":"State Key Laboratory of Oncology in South China, Guangzhou, People\u2019s Republic of China"},{"name":"Collaborative Innovation Center for Cancer Medicine, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[{"name":"Medical Oncology of Sun Yat-sen University Cancer Center, Guangzhou, People\u2019s Republic of China"},{"name":"State Key Laboratory of Oncology in South China, Guangzhou, People\u2019s Republic of China"},{"name":"Collaborative Innovation Center for Cancer Medicine, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning-Ning","family":"Zhou","sequence":"additional","affiliation":[{"name":"Medical Oncology of Sun Yat-sen University Cancer Center, Guangzhou, People\u2019s Republic of China"},{"name":"State Key Laboratory of Oncology in South China, Guangzhou, People\u2019s Republic of China"},{"name":"Collaborative Innovation Center for Cancer Medicine, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Yun","family":"Zhao","sequence":"additional","affiliation":[{"name":"Medical Oncology of Sun Yat-sen University Cancer Center, Guangzhou, People\u2019s Republic of China"},{"name":"State Key Laboratory of Oncology in South China, Guangzhou, People\u2019s Republic of China"},{"name":"Collaborative Innovation Center for Cancer Medicine, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[{"name":"Medical Oncology of Sun Yat-sen University Cancer Center, Guangzhou, People\u2019s Republic of China"},{"name":"State Key Laboratory of Oncology in South China, Guangzhou, People\u2019s Republic of China"},{"name":"Collaborative Innovation Center for Cancer Medicine, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,1,17]]},"reference":[{"key":"2021122506430005700_onco12053-bib-0001","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/thx.2003.020164","article-title":"Chemotherapy versus supportive care in advanced non-small cell lung cancer: Improved survival without detriment to quality of life","volume":"59","author":"Spiro","year":"2004","journal-title":"Thorax"},{"issue":"suppl 5","key":"2021122506430005700_onco12053-bib-0002","first-page":"S9","article-title":"Palliative care: Optimizing quality of life","volume":"105","author":"Kim","year":"2005","journal-title":"J Am Osteopath Assoc"},{"key":"2021122506430005700_onco12053-bib-0003","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.clon.2007.11.007","article-title":"Time and chemotherapy treatment trends in the treatment of elderly patients (age\u226570 years) with non-small cell lung cancer","volume":"20","author":"O\u2019Brien","year":"2008","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2021122506430005700_onco12053-bib-0004","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jnci.2015.02.001","article-title":"End-of-life palliative chemotherapy: Where do we stand?","volume":"27","author":"Mohammed","year":"2015","journal-title":"J Egypt Natl Canc Inst"},{"key":"2021122506430005700_onco12053-bib-0005","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1001\/jama.299.22.2667","article-title":"The role of chemotherapy at the end of life: \u201cWhen is enough, enough?\u201d","volume":"299","author":"Harrington","year":"2008","journal-title":"JAMA"},{"key":"2021122506430005700_onco12053-bib-0006","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1200\/JCO.2004.08.136","article-title":"Trends in the aggressiveness of cancer care near the end of life","volume":"22","author":"Earle","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122506430005700_onco12053-bib-0007","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdq778","article-title":"Palliative chemotherapy during the last month of life","volume":"22","author":"N\u00e4pp\u00e4","year":"2011","journal-title":"Ann Oncol"},{"key":"2021122506430005700_onco12053-bib-0008","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/jamaoncol.2015.2378","article-title":"Chemotherapy use, performance status, and quality of life at the end of life","volume":"1","author":"Prigerson","year":"2015","journal-title":"JAMA Oncol"},{"key":"2021122506430005700_onco12053-bib-0009","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJMoa1000678","article-title":"Early palliative care for patients with metastatic non-small-cell lung cancer","volume":"363","author":"Temel","year":"2010","journal-title":"N Engl J Med"},{"key":"2021122506430005700_onco12053-bib-0010","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2011.35.7996","article-title":"Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small cell lung cancer","volume":"30","author":"Greer","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122506430005700_onco12053-bib-0011","doi-asserted-by":"crossref","first-page":"4613","DOI":"10.1200\/JCO.2008.20.5096","article-title":"Determinants of aggressive end-of-life care for Taiwanese cancer decedents, 2001 to 2006","volume":"27","author":"Tang","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122506430005700_onco12053-bib-0012","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1472-684X-13-26","article-title":"Chemotherapy near the end of life: A retrospective single-centre analysis of patients\u2019 charts","volume":"13","author":"Adam","year":"2014","journal-title":"BMC Palliat Care"},{"key":"2021122506430005700_onco12053-bib-0013","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/pon.1140","article-title":"The aggressiveness of cancer care in the last three months of life: A retrospective single centre analysis","volume":"16","author":"Braga","year":"2007","journal-title":"Psychooncology"},{"key":"2021122506430005700_onco12053-bib-0014","doi-asserted-by":"crossref","first-page":"e492","DOI":"10.1016\/S1470-2045(12)70380-7","article-title":"Supportive, palliative, and end-of-life care for patients with cancer in Asia: Resource-stratified guidelines from the Asian Oncology Summit 2012","volume":"13","author":"Payne","year":"2012","journal-title":"Lancet Oncol"},{"key":"2021122506430005700_onco12053-bib-0015","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1089\/jpm.2012.9579","article-title":"Medicalization of dying: Are we turning the corner?","volume":"15","author":"Goh","year":"2012","journal-title":"J Palliat Med"},{"key":"2021122506430005700_onco12053-bib-0016","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/S0140-6736(08)61368-9","article-title":"Reform of how health care is paid for in China: Challenges and opportunities","volume":"372","author":"Hu","year":"2008","journal-title":"Lancet"},{"key":"2021122506430005700_onco12053-bib-0017","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1200\/JCO.2010.32.4459","article-title":"Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: Results of a randomized study of early palliative care","volume":"29","author":"Temel","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122506430005700_onco12053-bib-0018","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s005200050289","article-title":"The difficult choice of chemotherapy in patients with unresectable non-small-cell lung cancer","volume":"8","author":"Tamburini","year":"2000","journal-title":"Support Care Cancer"},{"key":"2021122506430005700_onco12053-bib-0019","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2354.2006.00685.x","article-title":"Traditional Chinese medicine in cancer care: Perspectives and experiences of patients and professionals in China","volume":"15","author":"Xu","year":"2006","journal-title":"Eur J Cancer Care (Engl)"},{"key":"2021122506430005700_onco12053-bib-0020","doi-asserted-by":"crossref","first-page":"639","DOI":"10.7326\/0003-4819-138-8-200304150-00011","article-title":"Chemotherapy use among Medicare beneficiaries at the end of life","volume":"138","author":"Emanuel","year":"2003","journal-title":"Ann Intern Med"},{"key":"2021122506430005700_onco12053-bib-0021","doi-asserted-by":"crossref","first-page":"g1219","DOI":"10.1136\/bmj.g1219","article-title":"Associations between palliative chemotherapy and adult cancer patients\u2019 end of life care and place of death: Prospective cohort study","volume":"348","author":"Wright","year":"2014","journal-title":"BMJ"},{"key":"2021122506430005700_onco12053-bib-0022","doi-asserted-by":"crossref","first-page":"e460","DOI":"10.1097\/MD.0000000000000460","article-title":"Determinants for aggressive end-of-life care for oral cancer patients: A population-based study in an Asian country","volume":"94","author":"Chang","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"2021122506430005700_onco12053-bib-0023","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1177\/0269216311406989","article-title":"Impact of age on end-of-life care for adult Taiwanese cancer decedents, 2001-2006","volume":"26","author":"Tang","year":"2012","journal-title":"Palliat Med"},{"key":"2021122506430005700_onco12053-bib-0024","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1200\/JCO.2007.15.8253","article-title":"Aggressiveness of cancer care near the end of life: Is it a quality-of-care issue?","volume":"26","author":"Earle","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122506430005700_onco12053-bib-0025","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1200\/JCO.2010.31.9897","article-title":"Trends in the aggressiveness of end-of-life cancer care in the universal health care system of Ontario, Canada","volume":"29","author":"Ho","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122506430005700_onco12053-bib-0026","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1472-684X-10-14","article-title":"The effect on survival of continuing chemotherapy to near death","volume":"10","author":"Saito","year":"2011","journal-title":"BMC Palliat Care"},{"key":"2021122506430005700_onco12053-bib-0027","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2004.11.037","article-title":"Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment","volume":"22","author":"Grothey","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122506430005700_onco12053-bib-0028","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature04296","article-title":"Oncogenic pathway signatures in human cancers as a guide to targeted therapies","volume":"439","author":"Bild","year":"2006","journal-title":"Nature"},{"key":"2021122506430005700_onco12053-bib-0029","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nrc2947","article-title":"Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer","volume":"10","author":"Pao","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"2021122506430005700_onco12053-bib-0030","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5732\/cjc.013.10011","article-title":"Molecular markers as therapeutic targets in lung cancer","volume":"32","author":"Tseng","year":"2013","journal-title":"Chin J Cancer"},{"key":"2021122506430005700_onco12053-bib-0031","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11523-015-0373-x","article-title":"Is there a survival benefit of first-line epidermal growth factor receptor tyrosine-kinase inhibitor monotherapy versus chemotherapy in patients with advanced non-small-cell lung cancer?: A meta-analysis","volume":"11","author":"Guetz","year":"2016","journal-title":"Target Oncol"},{"key":"2021122506430005700_onco12053-bib-0032","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.3747\/co.22.2566","article-title":"Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: A systematic review","volume":"22","author":"Ellis","year":"2015","journal-title":"Curr Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2016-0013","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2016-0013","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/1\/53\/41913386\/oncolo_22_1_53.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/1\/53\/41913386\/oncolo_22_1_53.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T06:44:09Z","timestamp":1640414649000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/22\/1\/53\/6438552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,1]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,1,17]]},"published-print":{"date-parts":[[2017,1,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2016-0013","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,1,1]]},"published":{"date-parts":[[2017,1,1]]}}}